Camlin Fine Sciences Q3FY26 Revenue Up 6.1% to ₹4,572 Crore, Vinpai Acquisition Contributes
Camlin Fine Sciences reported Q3FY26 revenue of ₹457.2 Crore, up 6.1% YoY. Nine-month revenue reached ₹1,340.6 Crore, up 9%. EBITDA was ₹30.7 Crore with a 6.7% margin. The company acquired a majority stake in Vinpai, contributing ₹12.9 Crore revenue in Q3FY26. Outlook remains positive for Vanillin and Blends businesses.
The revenue growth and strategic acquisition are positive factors. However, the fire incident and challenges in specific business segments introduce some uncertainty, resulting in a medium impact.
The company reported revenue growth and highlighted strategic acquisition, but also mentioned challenges in the Vanillin business and a fire incident in Brazil, leading to a neutral sentiment.
Camlin Fine Sciences Limited announced its investor presentation for the conference call discussing the un-audited financial results for the quarter and nine months ended December 31, 2025. The company reported a consolidated revenue of ₹4,572 million (₹457.2 Crore) for Q3FY26, marking a 6.1% year-on-year growth. Revenue for the nine months ended December 31, 2025, stood at ₹13,406 million (₹1,340.6 Crore), an increase of 9% YoY.
The company's EBITDA for Q3FY26 was ₹307 million (₹30.7 Crore) with a margin of 6.7%. The Blends business demonstrated steady growth across key markets. The acquisition of a controlling stake in Vinpai on November 30, 2025, contributed ₹129 million (₹12.9 Crore) to the revenue in Q3FY26. The Vanillin business faced challenges due to tariff-related issues, but the company expects improvements in subsequent quarters due to tariff withdrawal.
A fire incident was reported at one of the Brazil units on February 7, 2026, with loss assessment by the insurer in progress. Operations at the affected unit are suspended, and alternative arrangements are being made. CFS Europe is likely to be liquidated, which would curtail losses from discontinued operations. The company anticipates improvements in Vanillin business realization and volume, and sustained growth in the Blends segment for the remainder of the financial year, despite challenges in CFS Brazil.
Camlin Fine Sciences also highlighted its strategic acquisition of a majority stake (~83.82%) in Vinpai, which specializes in algae and plant-based functional ingredients. This acquisition aims to diversify its portfolio, expand market reach, enhance R&D capabilities, drive financial growth, and create cross-selling opportunities, particularly in the food, cosmetics, and nutraceuticals industries.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.